Stay updated on Reslizumab in EGPA: Clinical Trial
Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.

Latest updates to the Reslizumab in EGPA: Clinical Trial page
- Check3 days agoChange DetectedRevision updated from v3.6.0 to v3.6.3, signaling a new page build. This update reflects a platform or asset patch rather than changes to the study data or presentation of the trial details.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedNew navigation and guidance links were added to help users check eligibility, locate contact information, read the study record, and learn how to join the study. A formatting tweak to the Intervention/Treatment header and a revision tag update from v3.5.5 to v3.6.0 were applied.SummaryDifference0.5%

- Check24 days agoChange DetectedThe page's revision label was updated from v3.5.4 to v3.5.5. This indicates a new deployment or update to the page without changing the study information.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page now displays a new revision tag (Revision: v3.5.4), indicating an administrative update to the page.SummaryDifference0.1%

- Check53 days agoChange DetectedThe 'Last known status' section, including the investigator's name and affiliation and the verification line, was removed from the study record. This changes what provenance details are visible on the page, affecting traceability of the study's status history.SummaryDifference0.4%

- Check67 days agoChange DetectedThe page’s display revision/version label was updated from v3.5.2 to v3.5.3, indicating a site software update without changing the underlying study information.SummaryDifference0.1%

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.